These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
102 related articles for article (PubMed ID: 20937320)
1. Generation of an immune microenvironment as a novel mechanism for myotoxins to potentiate genetic vaccines. Qin H; Cha SC; Neelapu SS; Liu C; Wang YH; Wei J; Qin XF; Liu YJ; Kwak LW Vaccine; 2010 Nov; 28(50):7970-8. PubMed ID: 20937320 [TBL] [Abstract][Full Text] [Related]
2. A TLR9 agonist enhances therapeutic effects of telomerase genetic vaccine. Conforti A; Cipriani B; Peruzzi D; Dharmapuri S; Kandimalla ER; Agrawal S; Mori F; Ciliberto G; La Monica N; Aurisicchio L Vaccine; 2010 Apr; 28(20):3522-30. PubMed ID: 20332048 [TBL] [Abstract][Full Text] [Related]
3. [Frontier of mycobacterium research--host vs. mycobacterium]. Okada M; Shirakawa T Kekkaku; 2005 Sep; 80(9):613-29. PubMed ID: 16245793 [TBL] [Abstract][Full Text] [Related]
4. Toll-like receptor-dependent activation of antigen-presenting cells affects adaptive immunity to Helicobacter pylori. Rad R; Brenner L; Krug A; Voland P; Mages J; Lang R; Schwendy S; Reindl W; Dossumbekova A; Ballhorn W; Wagner H; Schmid RM; Bauer S; Prinz C Gastroenterology; 2007 Jul; 133(1):150-163.e3. PubMed ID: 17631139 [TBL] [Abstract][Full Text] [Related]
5. Dendritic cells engineered to express the Flt3 ligand stimulate type I immune response, and induce enhanced cytoxic T and natural killer cell cytotoxicities and antitumor immunity. Liu Y; Huang H; Chen Z; Zong L; Xiang J J Gene Med; 2003 Aug; 5(8):668-80. PubMed ID: 12898636 [TBL] [Abstract][Full Text] [Related]
6. TLR ligand suppression or enhancement of Treg cells? A double-edged sword in immunity to tumours. Conroy H; Marshall NA; Mills KH Oncogene; 2008 Jan; 27(2):168-80. PubMed ID: 18176598 [TBL] [Abstract][Full Text] [Related]
7. AS04, an aluminum salt- and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity. Didierlaurent AM; Morel S; Lockman L; Giannini SL; Bisteau M; Carlsen H; Kielland A; Vosters O; Vanderheyde N; Schiavetti F; Larocque D; Van Mechelen M; Garçon N J Immunol; 2009 Nov; 183(10):6186-97. PubMed ID: 19864596 [TBL] [Abstract][Full Text] [Related]
8. CD40-expressing plasmid induces anti-CD40 antibody and enhances immune responses to DNA vaccination. Xu H; Zhao G; Huang X; Ding Z; Wang J; Wang X; Cheng Y; Kang Y; Wang B J Gene Med; 2010 Jan; 12(1):97-106. PubMed ID: 19950201 [TBL] [Abstract][Full Text] [Related]
9. Ampligen: a potential toll-like 3 receptor adjuvant for immunotherapy of cancer. Jasani B; Navabi H; Adams M Vaccine; 2009 May; 27(25-26):3401-4. PubMed ID: 19200817 [TBL] [Abstract][Full Text] [Related]
10. Dendritic cells from bench to bedside and back. Adema GJ Immunol Lett; 2009 Feb; 122(2):128-30. PubMed ID: 19121337 [TBL] [Abstract][Full Text] [Related]
11. Combined Toll-like receptor agonists synergistically increase production of inflammatory cytokines in human neonatal dendritic cells. Krumbiegel D; Zepp F; Meyer CU Hum Immunol; 2007 Oct; 68(10):813-22. PubMed ID: 17961769 [TBL] [Abstract][Full Text] [Related]
12. CD40-mediated up-regulation of Toll-like receptor 4-MD2 complex on the surface of murine dendritic cells. Frleta D; Noelle RJ; Wade WF J Leukoc Biol; 2003 Dec; 74(6):1064-73. PubMed ID: 12960264 [TBL] [Abstract][Full Text] [Related]
14. PIKA as an adjuvant enhances specific humoral and cellular immune responses following the vaccination of mice with HBsAg plus PIKA. Shen E; Li L; Li L; Feng L; Lu L; Yao Z; Lin H; Wu C Cell Mol Immunol; 2007 Apr; 4(2):113-20. PubMed ID: 17484805 [TBL] [Abstract][Full Text] [Related]
15. Expression and function of Toll-like receptors on dendritic cells and other antigen presenting cells from non-human primates. Ketloy C; Engering A; Srichairatanakul U; Limsalakpetch A; Yongvanitchit K; Pichyangkul S; Ruxrungtham K Vet Immunol Immunopathol; 2008 Sep; 125(1-2):18-30. PubMed ID: 18571243 [TBL] [Abstract][Full Text] [Related]
16. Multiple CD4 and CD8 T-cell activation parameters predict vaccine efficacy in vivo mediated by individual DC-activating agonists. Welters MJ; Bijker MS; van den Eeden SJ; Franken KL; Melief CJ; Offringa R; van der Burg SH Vaccine; 2007 Feb; 25(8):1379-89. PubMed ID: 17123670 [TBL] [Abstract][Full Text] [Related]